Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tonix Pharma ( (TNXP) ) has shared an update.
On March 24, 2025, Tonix Pharmaceuticals announced that the FDA will not require an Advisory Committee meeting for the New Drug Application of TNX-102 SL, a product candidate for fibromyalgia management. This development could streamline the approval process, potentially accelerating the product’s market entry and impacting the company’s operations and market positioning positively.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing innovative therapies for central nervous system disorders, immunology, and infectious diseases. Their primary product candidates include TNX-102 SL for fibromyalgia management.
YTD Price Performance: -30.17%
Average Trading Volume: 1,541,769
Technical Sentiment Signal: Buy
Current Market Cap: $148.2M
See more data about TNXP stock on TipRanks’ Stock Analysis page.